WASHINGTON — President Trump’s forthcoming proposal to lower the cost of expensive physician-administered drugs will hit three drug companies — Amgen, Genentech, and Regeneron — harder than anyone else.
Trump is expected to roll out a pilot program Thursday that would tie reimbursement for certain expensive drugs to the prices paid in other similar countries, POLITICO reports. And the Department of Health and Human Services is already out with a report that names the specific drug companies that charge more for their medicines in the U.S. than in other countries.
The expected announcement comes as the Trump administration is increasingly taking direct aim at the pharmaceutical industry after months of nibbling around the edges. Drug companies are still reeling from the administration’s recent proposal to require prices in TV ads. And there are hints, too, that a new Medicare payment rule that’s expected to include changes to drug pricing policy could be unveiled as early as Thursday afternoon.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
